AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12027069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biminne (dose-response study)
Number of subjects: 58
Study 12027069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biminne treatment
Number of subjects: 58
Study 9500317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin (trough blood concentrations of 75-125 ng/mL)
Number of subjects: 231
Study 9500317 — intervention group
Group type: COMPARATOR
Intervention: Normal-dose cyclosporin (trough blood concentrations of 150-250 ng/mL)
Number of subjects: 231
Study 9500317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 231
Study 9500317 — intervention group
Group type: COMPARATOR
Intervention: Normal-dose cyclosporin
Number of subjects: 231
Study 7886650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (100 micrograms/puff or 200 micrograms/puff)
Number of subjects: 18
Study 7886650 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 18
Study 7886650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 18
Study 7886650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 18
Study 3174273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 19
Study 3174273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30601347 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered oximetry (artificially increasing saturation 3% points above true values)
Number of subjects: 0
Study 30601347 — intervention group
Group type: COMPARATOR
Intervention: True oximetry (true saturation values)
Number of subjects: 0
Study 30601347 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered oximetry
Number of subjects: 0
Study 30601347 — intervention group
Group type: COMPARATOR
Intervention: True oximetry
Number of subjects: 0
Study 29392894 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 5
Number of subjects: 90
Study 29392894 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 7
Number of subjects: 90
Study 29392894 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 8.4
Number of subjects: 90
Study 29392894 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (all pH values)
Number of subjects: 90
Study 29392894 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-stained)
Number of subjects: 90
Study 28676200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar Box Arthroscopy Trainer (CBAT)
Number of subjects: 24
Study 28676200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic Knee Arthroscopy Trainer (AKAT)
Number of subjects: 24
Study 28676200 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic training)
Number of subjects: 24
Study 25775672 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis
Number of subjects: 83
Study 25775672 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 83
Study 23736733 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 120
Study 23736733 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle-intensive medical management
Number of subjects: 120
Study 21989185 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of anthracycline chemotherapy
Number of subjects: 1000
Study 21989185 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1000
Study 19052541 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex ER + Olanzapine
Number of subjects: 402
Study 19052541 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex ER + Risperidone
Number of subjects: 402
Study 19052541 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 402
Study 19052541 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 402
Study 19052541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 402
Study 17287823 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI‐34041 (10, 50, or 100 mg)
Number of subjects: 24
Study 17287823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14766394 — intervention group
Group type: EXPERIMENTAL
Intervention: Spheramine (cultured human retinal pigment epithelial cells attached to microcarriers)
Number of subjects: 6
Study 14766394 — intervention group
Group type: EXPERIMENTAL
Intervention: Spheramine
Number of subjects: 6
Study 11136171 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C concentration
Number of subjects: 41
Study 11136171 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) measured using inulin clearance (C(in)) technique
Number of subjects: 41
Study 11136171 — intervention group
Group type: COMPARATOR
Intervention: Plasma creatinine concentration
Number of subjects: 41
Study 11136171 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum cystatin C concentration and C(in)
Number of subjects: 41
Study 11136171 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR less than the lower 95% confidence interval
Number of subjects: 41
Study 11136171 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C concentration greater than the upper 95% confidence interval
Number of subjects: 41
Study 9082927 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0
Study 9082927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7944433 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal infusion chemotherapy (n=5)
Number of subjects: 19
Study 7944433 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (n=6)
Number of subjects: 19
Study 7944433 — intervention group
Group type: COMPARATOR
Intervention: Arterial infusion chemotherapy (n=8)
Number of subjects: 19
Study 3984837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (1.0 mg/kg IV, then 1 mg/kg increments to a maximum of 3.0 mg/kg)
Number of subjects: 33
Study 3984837 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (1000 mg IV, then 1500 mg)
Number of subjects: 33
Study 3984837 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral cibenzoline therapy (mean follow-up of 8.8 months)
Number of subjects: 33
Study 30477827 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg Zataria multiflora Boiss. (Shirazi thyme) powder twice daily for 12 weeks
Number of subjects: 85
Study 27538497 — intervention group
Group type: EXPERIMENTAL
Intervention: DA9301 (1000 mg/day for 4 weeks)
Number of subjects: 60
Study 27538497 — intervention group
Group type: EXPERIMENTAL
Intervention: DA9301
Number of subjects: 60
Study 27538497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25306810 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD), n = 129
Number of subjects: 249
Study 25306810 — intervention group
Group type: COMPARATOR
Intervention: Conventional circumcision (CC), n = 120
Number of subjects: 249
Study 22870258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low skeletal muscle index
Number of subjects: 174
Study 22870258 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Number of subjects: 174
Study 19819914 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel (group D)
Number of subjects: 237
Study 19819914 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G)
Number of subjects: 237
Study 18820037 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 42
Study 18820037 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated shoe inserts
Number of subjects: 42
Study 18820037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated shoe inserts (after switching from custom orthoses)
Number of subjects: 42
Study 18820037 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (after switching from prefabricated inserts)
Number of subjects: 42
Study 17547312 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type‐A (BTX‐A)
Number of subjects: 32
Study 17547312 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injection
Number of subjects: 32
Study 15077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (20 ppm administered 10 min after reperfusion)
Number of subjects: 20
Study 15077032 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas (administered 10 min after reperfusion)
Number of subjects: 20
Study 10680840 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF plasmid/liposome (P/L) gene transfer (1000 microg of VEGF)
Number of subjects: 15
Study 10680840 — intervention group
Group type: COMPARATOR
Intervention: beta-galactosidase plasmid/liposome (P/L) gene transfer (1000 microg of beta-galactosidase)
Number of subjects: 15
Study 10680840 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate (control)
Number of subjects: 15
Study 10680840 — intervention group
Group type: COMPARATOR
Intervention: Control angiography after 6 months
Number of subjects: 15
Study 9377618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 1655
Study 9377618 — intervention group
Group type: COMPARATOR
Intervention: H2RAs (ranitidine, famotidine, cimetidine, roxatidine)
Number of subjects: 1655
Study 8245283 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management (IMI-CM)
Number of subjects: 250
Study 8245283 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 250
Study 8245283 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 250
Study 8245283 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo plus clinical management
Number of subjects: 250
Study 4037168 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR WISE asthma self-management program
Number of subjects: 14
Study 4037168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 30415650 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (sugar-coated tablet)
Number of subjects: 36
Study 30415650 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (film-coated tablet)
Number of subjects: 36
Study 30415650 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (both formulations)
Number of subjects: 36
Study 29169170 — intervention group
Group type: COMPARATOR
Intervention: Open and double-blind placebo-controlled food challenges (DBPCFC)
Number of subjects: 51
Study 29169170 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM-induced asthma and anti-mite IgE levels
Number of subjects: 51
Study 26414089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 29
Study 26414089 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 29
Study 22796389 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) application over the rectus femoris, vastus lateralis and vastus medialis muscles
Number of subjects: 60
Study 22796389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelastic adhesive tape application over the rectus femoris, vastus lateralis and vastus medialis muscles
Number of subjects: 60
Study 22796389 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 min at rest)
Number of subjects: 60
Study 22796389 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) application
Number of subjects: 60
Study 22796389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelastic adhesive tape application
Number of subjects: 60
Study 21127897 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary running on dry land
Number of subjects: 12
Study 21127897 — intervention group
Group type: COMPARATOR
Intervention: Stationary running in water
Number of subjects: 12
Study 21127897 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal cadences
Number of subjects: 12
Study 21127897 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal velocity
Number of subjects: 12
Study 19247757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 5% lidocaine plus naphazoline solution 0.2 mg ml(‐1)
Number of subjects: 28
Study 19247757 — intervention group
Group type: COMPARATOR
Intervention: Topical intranasal saline 20 ml (control group)
Number of subjects: 28
Study 16426087 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 1800
Study 15616477 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support model (supported employment)
Number of subjects: 176
Study 15616477 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial rehabilitation program (transitional employment)
Number of subjects: 176
Study 15616477 — intervention group
Group type: COMPARATOR
Intervention: Standard services
Number of subjects: 176
Study 10768245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g i.v. 30 min preinterventionally
Number of subjects: 216
Study 10768245 — intervention group
Group type: COMPARATOR
Intervention: No study medication (control group)
Number of subjects: 216
Study 9357093 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (500 mg sodium valproate) under fasting conditions (treatment A)
Number of subjects: 12
Study 9357093 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (500 mg sodium valproate) after ingestion of 14 g citrus pectin (treatment B)
Number of subjects: 12
Study 8375437 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ without stone manipulation
Number of subjects: 120
Study 8375437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass stones with stent
Number of subjects: 120
Study 8375437 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a catheter below stone with continuous saline irrigation
Number of subjects: 120
Study 3081599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg)
Number of subjects: 12
Study 3081599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (12 doses of 20 mg)
Number of subjects: 12
Study 3081599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (single dose)
Number of subjects: 12
Study 3081599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30767715 — intervention group
Group type: EXPERIMENTAL
Intervention: Online opioid overdose prevention training (OOPT)
Number of subjects: 100
Study 30767715 — intervention group
Group type: COMPARATOR
Intervention: In-person opioid overdose prevention training (OOPT)
Number of subjects: 100
Study 29098749 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific go/no-go training
Number of subjects: 0
Study 29098749 — intervention group
Group type: COMPARATOR
Intervention: General inhibitory control training
Number of subjects: 0
Study 26723484 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 60
Study 26723484 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation + Calcium Hydroxide (CH)
Number of subjects: 60
Study 26723484 — intervention group
Group type: COMPARATOR
Intervention: TheraCal LC
Number of subjects: 60
Study 26723484 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation + TheraCal LC
Number of subjects: 60
Study 24720924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal cardiovascular events
Number of subjects: 2556
Study 24720924 — intervention group
Group type: COMPARATOR
Intervention: No nonfatal cardiovascular events
Number of subjects: 2556
Study 23167682 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0
Study 23167682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20496791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporobakterin liquid, a suspension for oral use
Number of subjects: 38
Study 18606726 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-evaluative task (SET) condition
Number of subjects: 89
Study 18606726 — intervention group
Group type: COMPARATOR
Intervention: Nonexplicitly evaluative conditions
Number of subjects: 89
Study 18606726 — intervention group
Group type: EXPERIMENTAL
Intervention: SET condition
Number of subjects: 89
Study 16098081 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a 180 mg/week with ribavirin for 48 weeks
Number of subjects: 20
Study 16098081 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alpha-2a 180 mg/week without ribavirin for 48 weeks
Number of subjects: 20
Study 16098081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon/ribavirin)
Number of subjects: 20
Study 16098081 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable RNA at 12 weeks
Number of subjects: 20
Study 16098081 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <18 years
Number of subjects: 20
Study 12164887 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSite System with 70% isopropyl alcohol
Number of subjects: 104
Study 12164887 — intervention group
Group type: COMPARATOR
Intervention: Tesio-Cath
Number of subjects: 104
Study 12164887 — intervention group
Group type: COMPARATOR
Intervention: LifeSite System with 0.2% sodium oxychlorosene
Number of subjects: 104
Study 10099040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten alone (400 mg)
Number of subjects: 18
Study 10099040 — intervention group
Group type: COMPARATOR
Intervention: Ceftibuten with antacid (Mylanta Double-Strength Liquid; 60 mL)
Number of subjects: 18
Study 10099040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten with ranitidine (150 mg/12 hours after 3 days of dosing)
Number of subjects: 18
Study 7706151 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-selected reinforcers
Number of subjects: 4
Study 7706151 — intervention group
Group type: COMPARATOR
Intervention: Experimenter-selected reinforcers
Number of subjects: 4
Study 2751753 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 30
Study 2751753 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 30
Study 999412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 20
Study 999412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 20
Study 999412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (combined with CPZ)
Number of subjects: 20
Study 999412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (combined with sulpiride)
Number of subjects: 20
Study 999412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31520242 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about oximetry and viewing an oximeter during training
Number of subjects: 20
Study 31520242 — intervention group
Group type: COMPARATOR
Intervention: Conventional paced breathing (no education or oximetry)
Number of subjects: 20
Study 28273549 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term tacrolimus (Tac) from -8 days to +30 days
Number of subjects: 174
Study 28273549 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine (CsA)
Number of subjects: 174
Study 28273549 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term tacrolimus (Tac)
Number of subjects: 174
Study 25666724 — intervention group
Group type: EXPERIMENTAL
Intervention: Metha™ femoral prosthesis
Number of subjects: 50
Study 25666724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanos™ femoral prosthesis
Number of subjects: 50
Study 23917662 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training (n=13)
Number of subjects: 29
Study 23917662 — intervention group
Group type: COMPARATOR
Intervention: Control (n=12)
Number of subjects: 29
Study 20924607 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 90
Study 20924607 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 0.5 g/kg at 12 h postnatal age
Number of subjects: 90
Study 20924607 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg at 12 h postnatal age
Number of subjects: 90
Study 20924607 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG group (both doses)
Number of subjects: 90
Study 19170847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch (TTP)
Number of subjects: 1094
Study 16689842 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 38
Study 16689842 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy (MI patients)
Number of subjects: 38
Study 16689842 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 38
Study 15569910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 220
Study 15569910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 220
Study 11251672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education on lifestyle (diet, exercise, smoking) with polypharmacological treatment
Number of subjects: 160
Study 11251672 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study 9924378 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (10 micrograms)
Number of subjects: 86
Study 9924378 — intervention group
Group type: COMPARATOR
Intervention: Control (anti-inflammatory drugs only)
Number of subjects: 86
Study 7816294 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla cream applied for at least 2 hours prior to injection
Number of subjects: 48
Study 7816294 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 48
Study 7816294 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo alpha
Number of subjects: 48
Study 7816294 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo beta
Number of subjects: 48
Study 3140155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% ophthalmic solution (Opticrom)
Number of subjects: 65
Study 3140155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching drug vehicle)
Number of subjects: 65
Study 30540619 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented EMG-triggered electrical stimulation therapy for wrist/finger extensors in addition to conventional physical therapy for 5 sessions a week for 4 weeks.
Number of subjects: 27